New Drug Eases Side Effects of Weight-Loss Drugs

Good news? Another medical breakthrough? Or Enhanced profits for Drug Companies?

Weight-Loss drugs (Ozempic, Wygovy, Mounjaro, et al) are the new in-thing! Everyone, it would appear, wants them in order to lose weight. Yet these drugs are not safe. In September 2025 it was reported that the first deaths had been reported, one death per week, according to the Sun newspaper. You will see that several large mainstream media outlets did report this, which was most unusual.Even the Conventional Medical Establishment has safety worries about these weight-loss drugs, saying they need to be taken under medical supervision, and their use restricted to people who have a clinical need for them - owing to the risk of potentially serious adverse reactions.

But none of this has limited an almost insatiable demand for the drugs. So people who cannot obtain them through normal health service channels are buying the drugs privately, on the internet, some of them, reputedly are ‘fake’ drugs, and thought to be even more dangerous.

So perhaps when Medscape reported that there was a new drug, NG101, that eases the side effects of weight-loss drugs it is good news? Medscape claimed that research showed that NG101“reduced nausea and vomiting in patients with obesity by 40% and 67% respectively”. However, the article fails to address 5 points.

1. The research, even if does not exaggerate the data, means that 60% of users of weight-loss drugs who suffer nausea will continue to suffer nausea; and 33% of users who suffer vomiting will continue to suffer vomiting.

2. Nausea and vomiting are two of the least serious ‘side effects’ of these drugs; certainly less serious than death; and perhaps less serious than some of the other ‘side effects’ admitted by conventional medicine, which include anxiety, blurred vision, confusion, constipation, diarrhoea, depression, fever, headache, indigestion, nightmares, seizures, tightness in the chest, trouble breathing, unusual tiredness or weakness, acid/sour stomach, heartburn, and much more.

3. The announcement is typical of pharmaceutical companies business plans, that is, to market and promote a drug which causes serious patient harm, and then to introduce another drug that ‘eases’ some of that patient harm cause by the first drug. A remarkable, and often-used business creation scheme!

4. Any side effects of the new drug, NG101, were (as usual) discounted! “No serious adverse events related to the study drug were reported in either group”. However, I am sure that we can expect that drug companies will now be looking for another drug, another business opportunity, to counter the side effects of NG101.

5. The study was funded by Neurogastric (and I will assume that NG101 is a product of this company). The author of the study, Sean Wharton, disclosed that he served as a consultant for Neurogastrix but did not declare that he was an investigator in the study.

And so on it goes. Medical breakthroughs are regularly announced by drug companies that are not medical breakthroughs. Here, the problem of obesity, caused largely by diet, but also by pharmaceutical drugs, is reaching epidemic proportions, and the pharmaceutical industry is seeking to enrich themselves.

Weight-Loss Drugs. The first fatalities have been announced, alongside other serious 'side effects.

Is this the second stage of another drug scandal? 

Wygovy, Oxempic and Mounjaro, as weight loss drugs, have been heavily promoted over the last 2+ years, despite conventional medicine knowing that they can cause serious adverse drug reactions. As usual, users of the drugs are not being informed about these ‘side effects’.

So back in February 2024 I asked the question - were we in the early stages of yet another medical scandal? And I reminded readers about the history of Acomplia, a weight loss drug that barely lasted two years before being banned.

Wygovy; Ozempic; Mounjaro: weight loss drugs, and the promotion of pharmaceutical drugs

Steven Scrutton

·

12 February 2024

The obesity/diabetes drugs, Wygovy, Ozempic, Mounjaro, have become a pharmaceutical best sellers. They are making the drug companies very wealthy! The active ingredient, semaglutide, helps control blood sugar, lowers appetite, and makes patients feel "full". The current claim of medical science is that all these semaglutide drugs can lead to weight loss…

Read full story

Now in Britain, the Sun newspaper has reported that the drugs are now being linked with one death every week. It is thought that in the UK alone there are now over 1.5 million people taking these drugs, the numbers rising after the NHS made them available in June 2025.

     “One death a week is now linked to weight loss injections, figures reveal. Jabs such as Ozempic, Wegovy and Mounjaro have been connected to 24 deaths in the 21 weeks since January. Linked fatalities logged by the Medicines and Healthcare products Regulatory Agency rose from 82 in January this year to 106 by June”.

Even so the paper tries to pull back when it says “It does not mean the injections, now being used by up to 1.5 million Britons, caused the deaths, only that they may have played a part”. Nor does it ask for an investigation into the possibility of drug-caused death to protect patients from drug harm. Indeed the article goes on to say that “On the basis of the current evidence, the benefits of GLP-1 medicines outweigh the potential risks when used for the licensed indications”. Who has made this statement? On what evidence has this judgement been made? We are not, of course, told!

The Independent Newspaper has also produced an article entitled, “Weight-loss jabs linked to hundreds of cases of life-threatening illness and 10 deaths”, adding that since the GLP-1 drugs, including Mounjaro, Ozempic and Wegovy, were licensed, there have been “hundreds of reported cases of acute and chronic pancreatitis among people taking them”. So it is not just death!

Several other news agencies have reported these deaths, which is unusual at this stage, such as the BBC, Sky News, Channel 4 News, even the British Medical Association, the Patient Safety Learning website, and even the Government website has seen fit to provide a “general reminder” about the known adverse reactions caused by the drugs. This is perhaps unusual - media outlets are generally quieter at this stage, in deference to their pharmaceutical paymasters!

However, this is the usual second-stage of an upcoming pharmaceutical scandal. The first stage is “the wonder drug” stage. The second stage concerns the denial, discounting, and justification of the harm caused to patients. Often, during this stage, conventional medicine seeks to find new uses and justifications for taking the drug, like this one recently reported on MIMS, “Semaglutide could correct prediabetes in people with schizophrenia on antibiotics”.

The third stage, for which we will now have to wait patiently, will come when the level and seriousness of patient harm becomes too difficult for government, conventional medicine, and the mainstream media to continue trying to justify.

So far, then, my prediction of another pharmaceutical medical scandal is on course!